(Q34956133)

5 August 2017

1 reference

title

Cellular immunity to the Her-2/neu protooncogene (English)

1 reference

5 August 2017

Rolf Kiessling

1

1 reference

5 August 2017

W Z Wei

2

1 reference

5 August 2017

F Herrmann

3

1 reference

5 August 2017

J A Lindencrona

4

1 reference

5 August 2017

A Choudhury

5

1 reference

5 August 2017

K Kono

6

1 reference

5 August 2017

B Seliger

7

1 reference

5 August 2017

publication date

1 January 2002

1 reference

Advances in Cancer Research

5 August 2017

published in

1 reference

5 August 2017

volume

85

1 reference

5 August 2017

page(s)

101-144

1 reference

Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

DNA vaccination: transfection and activation of dendritic cells as key events for immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

The optimization of helper T lymphocyte (HTL) function in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Amplification and over-expression of theEGFR anderbB-2 genes in human esophageal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Genetic immunization against neu/erbB2 transgenic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

HER-2/neu Oncogene Characterization in Head and Neck Squamous Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Human tumor antigens recognized by T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

High frequency of altered HLA class I phenotypes in invasive breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Kinetic Differences in Unresponsiveness of Thymus and Bone Marrow Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Structure of peptides associated with class I and class II MHC molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

The makings of a tumor rejection antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Mutated Ras peptides as vaccines in immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

TRAIL: a molecule with multiple receptors and control mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

A role for the proteasome regulator PA28alpha in antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

The N-terminal flanking region of the invariant chain peptide augments the immunogenicity of a cryptic "self" epitope from a tumor-associated antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2/neu Proto-oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

ElevatederbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Vaccination for malignant melanoma: recent developments

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/neu proto-oncogene expressed in ovarian carcinomas: related and unrelated to decreased MHC class 1 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Oncogene amplifications in early-stage human prostate carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

IgA production without mu or delta chain expression in developing B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Mechanisms of MHC class I--restricted antigen processing

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC I-dependent peptide trimming in the ER.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Shared T Cell Epitopes in Epithelial Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Degradation signals in ErbB-2 dictate proteasomal processing and immunogenicity and resist protection by cis glycine-alanine repeat

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

B cells inhibit induction of T cell-dependent tumor immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Pattern of expression of c-erbB-2 oncoprotein in human fetuses

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Expression of HER-2/neu in renal-cell carcinoma. Correlation with histologic subtypes and differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

The basic biology of HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Dendritic cells as adjuvants for immune-mediated resistance to tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Antigen-processing machinery breakdown and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Resistance of tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Development of a cancer vaccine: peptides, proteins, and DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Heat shock protein-peptide complexes in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Dendritic cells for the immunotherapy of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Serological analysis of human tumor antigens: molecular definition and implications

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Receptor protein-tyrosine kinases and their signal transduction pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture--no correlation with the postsurgical clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Auto-tumor immunity in patients with solid tumors: participation of CD3 complex and MHC class I antigens in the lytic interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Overexpression of HER2/neu oncogene in human pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

The requirement for proteasome activity class I major histocompatibility complex antigen presentation is dictated by the length of preprocessed antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2802%2985004-7

7 January 2021

10.1016/S0065-230X(02)85004-7

Identifiers

DOI

1 reference

5 August 2017

1 reference